Bayer Ready To File Elinzanetant After It Clears Third Phase III Hurdle

Will Compete With Sluggish Astellas Competitor

Bayer will submit its non-hormonal treatment for vasomotor symptoms associated with menopause for approvals this year, still eyeing €1bn-plus in peak sales despite a rival’s slow start.

Tired, stressed mature business woman suffering from neck pain, working from home office, sitting at table
Elinzanetant reduces hot flashes and may improve sleep in menopausal women • Source: Shutterstock

Bayer AG reported positive topline results from the third and final Phase III clinical trial of its non-hormonal treatment for vasomotor symptoms (VMS) associated with menopause on 19 March, declaring that it will now seek approvals for elinzanetant in multiple markets. This will pit the drug against a rival product, Astellas Pharma, Inc.’s Veozah (fezolinetant), which to date has seen sluggish sales that prompted the Japanese drug maker to lower its forecast for the product.

Key Takeaways
  • Bayer reported topline results from the third, final and longest Phase III trial of elinzanetant and plans to seek approvals later this year with launches expected in 2025.

Bayer has maintained its forecast that elinzanetant, a dual antagonist of the neurokinin 1 and 3 (NK-1,3) receptors, will achieve...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By 

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By 

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

More from R&D

Pipeline Watch: Five Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By 

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.